|
|
|
Hair Loss Study Abstract: Clinical experience with Diane-35, currently the lowest dose antiandrogenic hormonal ovulation inhibitor, in mild to moderative androgenization in the female
|
Title
[Clinical experience with Diane-35, currently the lowest dose antiandrogenic hormonal
ovulation inhibitor, in mild to moderative androgenization in the female]
Original Title
Klinische Erfahrungen mit Diane-35, dem zur Zeit niedrigst dosierten antiandrogen
wirkenden hormonalen Ovulationshemmer, bei leichten bis mittelstarken
Androgenisierungserscheinungen der Frau.
Author
Kaiser E
Source
Geburtshilfe Frauenheilkd, 46: 10, 1986 Oct, 738-42
Abstract
Low-dose hormonal contraceptives with specifically reduced estrogen are now the drug of
choice for the prevention of internal risks. The antiandrogenic hormonal contraceptives
have also had to be adapted to this situation. In a study involving 144 women, most of
whom were suffering from moderately severe androgenization, Diane-35 (reduced to 0.035 mg
ethinyl estradiol) was used as an antiandrogenically active hormonal contraceptive. From
the sixth treatment cycle onward acne and seborrhea were significantly improved or already
healed. In the 12th treatment cycle the treatment success rate was almost 90%. The side
effects occurring with higher-dose hormonal contraceptives were reduced, cycle behavior
was acceptable, and the incidence of metrorrhagia corresponded to that found with other
micropills.
Language of Publication
German
Unique Identifier
87106660
content2 |
|
